6533b85afe1ef96bd12b8bba

RESEARCH PRODUCT

Lubricin in synovial fluid of mild and severe temporomandibular joint internal derangements

Rosario Emanuele PerrottaLuis Eduardo AlmeidaRosalia LeonardiGiuseppe MusumeciCarla Loreto

subject

0301 basic medicinemedicine.medical_specialtyJoint cavitylubricin; synovial fluid; TMJGastroenterology03 medical and health sciences0302 clinical medicinesynovial fluidDisease severityInternal medicinemedicineHumansSynovial fluidStage (cooking)General DentistryGlycoproteinsVas scoreTemporomandibular Jointbusiness.industryResearch030206 dentistryTemporomandibular Joint Disorders:CIENCIAS MÉDICAS [UNESCO]Control subjectsTMJTemporomandibular jointSurgeryOrofacial Pain-TMJDCross-Sectional Studies030104 developmental biologymedicine.anatomical_structureOtorhinolaryngologyUNESCO::CIENCIAS MÉDICASSurgerylubricinStage ivbusiness

description

Background To understand the molecular basis of temporomandibular joint (TMJ) pathologies, we aimed to investigate the lubricin levels in the TMJ synovial fluid (SF) of patients with mild to severe internal derangements (IDs). Material and Methods A total, 34 joints were the study group. Only patients, with a Wilkes stage of III, IV and V were included, in this sample. Control group consisted of SF from eight joints, from patients undergoing to orthognatic surgery. Concentrations of lubricin in the SF from both samples were measured using ELISA system. Results The mean lubricin concentration was 7.029 ± 0.21 µg/mL in stage III patients; 5.64 ± 0.10 µg/mL in stage IV patients, and 4.78 ± 0.11 µg/mL in stage V patients. The lubricin levels from stage IV and stage V patients differed significantly (P ≤ 0.001) from those of control subjects. Lubricin levels were inversely correlated with age and to VAS score. Conclusions The results of this cross-sectional study highlight the relationship between disease severity and the levels of lubricin in TMJ SF. Our findings suggest that novel biotherapeutic approaches, including the administration of recombinant lubricin in the joint cavity, for the treatment of TMJ diseases can be developed. Key words:Lubricin, TMJ, derangements, synovial fluid.

10.4317/medoral.21145http://hdl.handle.net/20.500.11769/38859